John R. Mackey

TL;DR: The addition of 1 year of adjuvant trastuzumab significantly improved disease-free and overall survival among women with HER2-positive breast cancer and the risk-benefit ratio favored the nonanthracycline TCH regimen over AC-T plus trastzumab, given its similar efficacy, fewer acute toxic effects, and lower risks of cardiotoxicity and leukemia.

TL;DR: It is shown that understanding the biology and therapeutic responses of patients with TNBC will require the determination of individual tumour clonal genotypes, and for the first time in an epithelial tumour subtype, the relative abundance of clonal frequencies among cases representative of the population is determined.

TL;DR: Exercise is an effective intervention to improve quality of life, cardiorespiratory fitness, physical functioning and fatigue in breast cancer patients and survivors and larger trials that examine the long-term benefits of exercise are needed for this patient group.

TL;DR: Neither aerobic nor resistance exercise significantly improved cancer-specific QOL in breast cancer patients receiving chemotherapy, but they did improve self-esteem, physical fitness, body composition, and chemotherapy completion rate without causing lymphedema or significant adverse events.

TL;DR: Zoledronic acid (4 mg) via 15-minute intravenous infusion was as effective and well tolerated as 90 mg of pamidronate in the treatment of osteolytic and mixed bone metastases/lesions in patients with advanced breast cancer or multiple myeloma.